BR9713126A - Compounds derived from pyridin-2-yl-methylamine, process for its preparation, intermediate synthesis compounds, novel drug, and pharmaceutical composition - Google Patents
Compounds derived from pyridin-2-yl-methylamine, process for its preparation, intermediate synthesis compounds, novel drug, and pharmaceutical compositionInfo
- Publication number
- BR9713126A BR9713126A BR9713126-1A BR9713126A BR9713126A BR 9713126 A BR9713126 A BR 9713126A BR 9713126 A BR9713126 A BR 9713126A BR 9713126 A BR9713126 A BR 9713126A
- Authority
- BR
- Brazil
- Prior art keywords
- represents hydrogen
- compounds
- methyl
- fluorine
- pct
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 4
- 229910052801 chlorine Inorganic materials 0.000 abstract 4
- 239000000460 chlorine Substances 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 4
- 239000011737 fluorine Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- -1 cyclic amino Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
PCT No. PCT/FR97/02097 Sec. 371 Date May 21, 1999 Sec. 102(e) Date May 21, 1999 PCT Filed Nov. 20, 1997 PCT Pub. No. WO98/22459 PCT Pub. Date May 28, 1998The invention concerns novel pyridin-2-yl-methylamine derivatives of formula (I): in which: u represents hydrogen or methyl; v represents hydrogen, chlorine, or methyl; w represents hydrogen, fluorine, or methyl; x represents hydrogen or fluorine; y represents chlorine or methyl; z represents hydrogen, fluorine, chlorine, or methyl; A represents hydrogen, fluorine, chlorine, C1-C5 alkyl, fluoroalkyl, cyclopropyl, a 5-membered aromatic heterocyclic group, alkoxy or alkythio, amino, cyclic amino, or alkoxycarbonyl. These compounds are useful as medicines, in particular as antidepressants or analgesics.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9614217A FR2755967B1 (en) | 1996-11-21 | 1996-11-21 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
| PCT/FR1997/002097 WO1998022459A1 (en) | 1996-11-21 | 1997-11-20 | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9713126A true BR9713126A (en) | 2000-04-11 |
| BR9713126B1 BR9713126B1 (en) | 2009-01-13 |
Family
ID=9497861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9713126-1A BR9713126B1 (en) | 1996-11-21 | 1997-11-20 | pyridin-2-yl methylamine derivatives, process for their preparation, synthetic intermediate compounds, use of a compound, and pharmaceutical composition. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6020345A (en) |
| EP (1) | EP0946546B1 (en) |
| JP (1) | JP4248605B2 (en) |
| CN (1) | CN1098263C (en) |
| AT (1) | ATE243691T1 (en) |
| AU (1) | AU732470B2 (en) |
| BR (1) | BR9713126B1 (en) |
| CA (1) | CA2272460C (en) |
| DE (1) | DE69723104T2 (en) |
| DK (1) | DK0946546T3 (en) |
| ES (1) | ES2202647T3 (en) |
| FR (1) | FR2755967B1 (en) |
| PT (1) | PT946546E (en) |
| WO (1) | WO1998022459A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| FR2784378B1 (en) * | 1998-10-09 | 2000-12-29 | Pf Medicament | NOVEL ARYL- (4-FLUORO-4 - [(2-PYRIDIN-2-YL- ETHYLAMINO) -METHYL] -PIPERIDIN-1-YL) -METHANONE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS |
| US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ME00275B (en) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ?-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| HK1042251B (en) * | 1999-01-13 | 2012-07-20 | Bayer Healthcare Llc | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| FR2820743B1 (en) * | 2001-02-09 | 2005-02-25 | Pf Medicament | SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| DE10129320A1 (en) * | 2001-06-19 | 2003-04-10 | Norbert Mueller | Use of cyclooxygenase-2 inhibitor in the preparation of a medicament for treating psychiatric disorders e.g. schizophrenia |
| US20060167074A1 (en) * | 2001-06-19 | 2006-07-27 | Norbert Muller | Methods and compositions for the treatment of psychiatric disorders |
| FR2827172B1 (en) * | 2001-07-13 | 2004-07-02 | Pf Medicament | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES FOR THE TREATMENT OF OPIOID DEPENDENCE |
| US8106074B2 (en) | 2001-07-13 | 2012-01-31 | Pierre Fabre Medicament | Pyridin-2-yl-methylamine derivatives for treating opiate dependence |
| RS52500B (en) * | 2001-12-03 | 2013-04-30 | Bayer Healthcare Llc | Aryl of urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| AU2003209118A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| KR100435105B1 (en) * | 2002-04-17 | 2004-06-09 | 금호석유화학 주식회사 | Homogeneous Atom Transfer Radical Polymerization(ATRP) of Methyl Methacrylate(MMA) Using the Novel Catalysts Based on Carboximidate Ligand |
| FR2840900B1 (en) * | 2002-06-18 | 2005-02-25 | Pf Medicament | NOVEL ARYL [4-HALOGENO-4- [(HETEROARYL-METHYLAMINO) -METHYL] -PIPERIDIN-1-YL] -METHANONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
| UY28213A1 (en) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS. |
| FR2852244B1 (en) * | 2003-03-13 | 2007-09-07 | Pf Medicament | USE OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF SYMPTOMS OF CHRONIC PAIN OF NEUROPATHIC OR PSYCHOGENIC ORIGIN |
| PT1626714E (en) * | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | DIARILURIES FOR PDGFR MEDICATED DISEASES |
| DE602004010407T2 (en) * | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING |
| FR2891274B1 (en) * | 2005-09-27 | 2007-11-23 | Pierre Fabre Medicament Sa | PROCESS FOR PREPARING (3-CHLORO-4-FLUORO-PHENYL) - (4-FLUORO-4 - {[(5-METHYL-PYRIMIDIN-2-YLMETHYL) -AMINO] -METHYL] -PIPERIDIN-1-YL) METHANONE AND NEW INTERMEDIATE PYRIMIDINE DERIVATIVES. |
| EP2058306A1 (en) * | 2007-11-08 | 2009-05-13 | Schwarz Pharma Ag | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| WO2012145617A2 (en) * | 2011-04-22 | 2012-10-26 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| AU2015286675B2 (en) | 2014-07-09 | 2017-08-24 | Pierre Fabre Medicament | A method for treating movement disorders with befiradol |
| EP3260452A1 (en) * | 2016-06-24 | 2017-12-27 | Neurolixis | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-ht1a receptors |
| US10626105B2 (en) * | 2016-09-22 | 2020-04-21 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds |
| EP3664787B1 (en) | 2017-07-20 | 2022-07-20 | Neurolixis | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681325B1 (en) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | DERIVATIVES OF AMINOMETHYL-4 PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION. |
| EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
-
1996
- 1996-11-21 FR FR9614217A patent/FR2755967B1/en not_active Expired - Lifetime
-
1997
- 1997-11-20 AT AT97947107T patent/ATE243691T1/en active
- 1997-11-20 PT PT97947107T patent/PT946546E/en unknown
- 1997-11-20 JP JP52329298A patent/JP4248605B2/en not_active Expired - Lifetime
- 1997-11-20 US US09/308,613 patent/US6020345A/en not_active Expired - Lifetime
- 1997-11-20 ES ES97947107T patent/ES2202647T3/en not_active Expired - Lifetime
- 1997-11-20 CN CN97181172A patent/CN1098263C/en not_active Expired - Lifetime
- 1997-11-20 WO PCT/FR1997/002097 patent/WO1998022459A1/en not_active Ceased
- 1997-11-20 CA CA002272460A patent/CA2272460C/en not_active Expired - Lifetime
- 1997-11-20 EP EP97947107A patent/EP0946546B1/en not_active Expired - Lifetime
- 1997-11-20 BR BRPI9713126-1A patent/BR9713126B1/en not_active IP Right Cessation
- 1997-11-20 DE DE69723104T patent/DE69723104T2/en not_active Expired - Lifetime
- 1997-11-20 DK DK97947107T patent/DK0946546T3/en active
- 1997-11-20 AU AU52276/98A patent/AU732470B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001504129A (en) | 2001-03-27 |
| CA2272460A1 (en) | 1998-05-28 |
| CA2272460C (en) | 2009-11-17 |
| DE69723104T2 (en) | 2004-04-29 |
| FR2755967B1 (en) | 1999-01-29 |
| WO1998022459A1 (en) | 1998-05-28 |
| PT946546E (en) | 2003-11-28 |
| DE69723104D1 (en) | 2003-07-31 |
| JP4248605B2 (en) | 2009-04-02 |
| ES2202647T3 (en) | 2004-04-01 |
| US6020345A (en) | 2000-02-01 |
| AU732470B2 (en) | 2001-04-26 |
| AU5227698A (en) | 1998-06-10 |
| CN1242772A (en) | 2000-01-26 |
| FR2755967A1 (en) | 1998-05-22 |
| EP0946546A1 (en) | 1999-10-06 |
| ATE243691T1 (en) | 2003-07-15 |
| EP0946546B1 (en) | 2003-06-25 |
| BR9713126B1 (en) | 2009-01-13 |
| CN1098263C (en) | 2003-01-08 |
| DK0946546T3 (en) | 2003-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9713126A (en) | Compounds derived from pyridin-2-yl-methylamine, process for its preparation, intermediate synthesis compounds, novel drug, and pharmaceutical composition | |
| PT958296E (en) | HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND ITS UTILIZATION IN THE TREATMENT OF RELATED DIABETES AND DISEASES | |
| DE69725608D1 (en) | INDOLIN-2-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THE MEDICAMENT THEREOF | |
| NO305950B1 (en) | 1-amidinophenyl pyrrolidones, piperidinones, azetinones as platelet aggregation inhibitors and pharmaceutical compositions containing the compounds | |
| BR0211201A (en) | Compound, process for preparing such compound, use thereof, pharmaceutical composition comprising the same and method for treating a disease in a mammal | |
| LU91145I2 (en) | FIROCOXIB optionally in the form of a pharmaceutically acceptable salt (PREVICOX). | |
| DK1414439T3 (en) | New pyrroles with hypolipidemic and hypocholesterolemic activities, processes for their preparation and pharmaceutical compositions containing them and their use in medicine | |
| ATE411294T1 (en) | 4-AMINO-AZEPAN-3-ON DERIVATIVES AS PROTEASE INHIBITORS | |
| BR9908545A (en) | Piperidine derivative, process for preparing it, compound, process for preparing it, and pharmaceutical composition | |
| BR0209431A (en) | New 4-anilinoquinoline-3-carboxamides compounds | |
| NO20005715L (en) | Novel substituted cyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| AR004961A1 (en) | (R) - (-) - 2- {N- [4- (1,1-DIOXIDO-3- OXO-2,3-DIHIDRO-BENZISOTIAZOLE-2-IL) -BUTYL] -AMINOMETIL CRYSTALLINE V MODIFICATION ) CHROMAN, A PROCEDURE FOR ITS PREPARATION, MEDICINES CONTAINING IT, THE USE OF SUCH CHLORHYDRATE FOR THE PREPARATION OF MEDICINES, A COMPOSITION FOR | |
| NO308248B1 (en) | Compounds useful as antiproliferative agents and GARFT inhibitors, as well as pharmaceutical preparations | |
| BR0308145A (en) | Compound, pharmaceutical composition, use of a compound, and process for preparing a compound | |
| DK0994854T3 (en) | Process for the preparation of a substituted perhydroisoindole | |
| DE69611728D1 (en) | N- (4-SUBSTITUTED BENZYL) -2-AMINOLACTAM DERIVATIVES | |
| DK0891341T3 (en) | 1,3,4-Oxadiazine derivatives and their use as pesticides | |
| ATE172454T1 (en) | PYRIDAZINONE DERIVATIVES WITH PHARMACEUTICAL ACTION | |
| ATE311384T1 (en) | SULFUR CONTAINING COMPOUNDS CONTAINING AN AMIDE GROUP, METHOD FOR THEIR PRODUCTION, THEIR USE IN MEDICATIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| NO995685L (en) | New glycosylated ginkgold derivatives, their use as medicaments and pharmaceutical compositions | |
| DK1525188T3 (en) | Novel Derivatives of 4,4-Dithiobis (3-Aminobutane-1-Sulfonates) and Compositions Containing Them | |
| DK1257552T3 (en) | Xanthine derivatives, intermediates and use in the treatment of osteoporosis | |
| BR9610175A (en) | Compound preparation process of the pharmaceutical composition and use of the compound | |
| NO992870D0 (en) | Diphenylalkyl tetrahydropyridines, processes for their preparation, and pharmaceutical mixtures containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/02/2009, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 25.02.2019 |